Finnish pharmaceutical company Orion Corporation (HEL:ORNBV) and Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced on Thursday that Orion has obtained an exclusive commercial licence for one of Abzena's monoclonal antibodies targeting a cancer with high unmet clinical need.
This is expected to enhance Orion's oncology-focused research and development pipeline.
The antibody was developed at Abzena's Cambridge, UK, facility using its Composite Human Antibody (CHAb) technology and integrated developability platform. Abzena screened candidates for functionality, safety, and manufacturability to select a lead without downstream development risks.
A highly stable manufacturing cell line was generated using Abzena's AbZelectPRO cell line development platform. Abzena supports antibody programmes at its Cambridge and San Diego facilities, with downstream process development and GMP manufacturing up to 2,000 litres in the United States.
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio